Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
227 EUR | +3.65% | +6.82% | -14.34% |
Apr. 24 | SARTORIUS VORZUEGE : Gets a Buy rating from Berenberg | ZD |
Apr. 23 | SARTORIUS VORZUEGE : DZ Bank gives a Sell rating | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 77.74 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.34% | 19.08B | - | ||
-46.21% | 2.65B | C+ | ||
+18.15% | 1.87B | - | - | |
-3.12% | 1.61B | - | ||
+23.78% | 1.21B | B+ | ||
-10.69% | 1.02B | - | ||
-20.89% | 905M | - | C- | |
-7.14% | 716M | - | ||
-18.10% | 682M | B+ | ||
+4.01% | 480M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- SRT Stock
- Ratings Sartorius AG